NEW YORK (GenomeWeb) – Response Genetics reported today a roughly 3 percent drop in its first quarter revenues as an increase in test order volume was offset by lower reimbursement.

The Los Angeles-based molecular diagnostic testing services firm reported total revenues of $3.8 million for the three months ended March 31, down from $3.9 million in Q1 2014. It said that sales associated with its ResponseDx tests were $3.3 million, consistent with the first quarter of 2014. However, its pharmaceutical client revenue slipped to $500,000 from $600,000 year over year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.